Highest-materiality recent filing
Heron Therapeutics extends Tax Benefit Preservation Plan to August 14, 2029
Amendment No. 1 to Tax Benefit Preservation Plan dated Aug 13, 2026 with Computershare Trust Company.
Heron Q2 revenue $37.7M (+1.3% YoY); withdraws FY2026 guidance on CINVANTI patent loss
Q2 net revenue $37.7M, up 1.3% YoY; Acute Care up 43.9%, Oncology down 15.9% (CINVANTI -9.7%, SUSTOL -77.5%).
Heron Therapeutics receives Nasdaq notice for bid price below $1.00; 180 days to cure
On June 25, 2026, Nasdaq notified Heron that its common stock closing bid price was below $1.00 for 30 consecutive trading days (May 12–June 24, 2026).
Stockholders approve all 6 proposals at 2026 Annual Meeting including equity plan increases
All 7 director nominees elected; Mr. Waage had lowest For votes at ~85.3M, broker non-votes ~50.1M.
Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit
U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.
Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed
Total net revenue $34.7M vs $38.9M YoY; Acute Care franchise up 32% led by ZYNRELEF (+27%) and APONVIE (+50%).
Heron Therapeutics amends CEO and executive severance, equity acceleration provisions
CEO Craig Collard's amended agreement: severance of 1x base salary + bonus (non-CIC) or 2x (CIC), plus equity acceleration.
Heron Therapeutics reports 2025 net revenue $154.9M, up 7.4%; issues 2026 guidance $173-183M
Full-year 2025 net revenue $154.9M (+7.4% YoY); Q4 net revenue $40.6M (-0.5% vs Q4 2024).
Heron Therapeutics preliminary Q4 2025 net revenue $40.5M; full-year $154.9M
Q4 2025 net revenue approximately $40.5M, driven by Acute Care franchise momentum.
Heron Q3 net revenue $38.2M, acute care +67% YoY, FY guidance reaffirmed
Q3 net revenue $38.2M (+16.5% YoY); YTD $114.3M.
Heron Therapeutics appoints Thomas Cusack to board under Rubric Capital agreement
Thomas Cusack appointed to Heron's board effective Oct 27, 2025; term expires at 2026 annual meeting.
Heron shareholders approve share issuances exceeding 19.99% threshold
On Oct 13, 2025, shareholders approved issuance of shares upon conversion of convertible notes due 2031 (89.6M for, 5.6M against).
Heron Therapeutics signs 111-month lease for 16,837 sq ft HQ in Cary, NC at $614,550/month base rent
New headquarters at 25 Fenton Main Street, Cary, NC; approximately 16,837 rentable square feet.
Heron Therapeutics adopts poison pill to protect $1.37B in NOLs from ownership change
Company holds ~$1.37B in U.S. federal NOLs as of Dec 31, 2024; plan aims to preserve tax asset.
Heron Therapeutics enters manufacturing/supply deal with Patheon, commits to 38,400 kg through 2026
Framework Agreement with Patheon Austria GmbH & Co KG, a Thermo Fisher unit, for manufacturing and supply of products.
Refinancing closed Aug 12: repurchased $125M of 2026 notes for cash, exchanged $25M for 16.67M shares; issued $35M notes due 2031 at $33.25M.
Q2 net revenue $37.2M (+3.3% YoY); year-to-date $76.1M (+7.7%); Acute Care revenue up 55.5% YoY.
Heron Therapeutics announces 2025 annual meeting results; all proposals approved
Stockholders elected all six director nominees: Collard, Dissanaike, Johnson, Kaseta, Morgan, Waage, each receiving >79M votes for.
Settlement resolves patent litigations in U.S. District Court for Delaware initiated in Sep 2023 and Jan 2024.
Net revenue of $38.9M, up 12.2% YoY; acute care franchise up 89.4% driven by ZYNRELEF (+60.4%).
Heron Therapeutics appoints Mark Hensley as COO effective April 28, 2025
Annual base salary of $553,000; target cash bonus of $276,500 (50% of base), prorated for 2025.
Heron Q4 net income $3.6M; FY2024 rev $144.2M (+14%); guides 2025 rev $153-163M
Q4 2024 GAAP net income of $3.6M; full-year 2024 adjusted EBITDA of $8.6M.
Extended maturity to earlier of Sept 1, 2027, or (if 1.5% convertible notes remain) May 12, 2026.
Heron Therapeutics moves HQ from San Diego to Cary, NC effective Jan 1, 2025
New corporate headquarters at 100 Regency Forest Dr, Suite 300, Cary, NC 27518.
Heron wins patent lawsuit against Fresenius Kabi over CINVANTI; generic blocked until 2035
Court ruled Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 valid and infringed by Fresenius Kabi's proposed generic CINVANTI.
Q3 acute care franchise net product sales $7.4M (+57% YoY); oncology franchise $25.4M (-5% YoY).
Heron Therapeutics appoints Michael Kaseta to Board of Directors
Michael Kaseta, CFO/COO of Liquidia, appointed to Heron's Board effective Nov. 4, 2024.
Heron Therapeutics Q2 net product sales $36.0M; narrows 2024 guidance
Q2 net product sales $36.0M, up from $31.8M YoY; acute care franchise $6.8M, oncology $29.2M.
FDA acknowledged receipt of Prior Approval Supplement for ZYNRELEF Vial Access Needle (bupivacaine/meloxicam); PDUFA goal date September 23, 2024.
Heron shareholders approve increase in authorized shares to 400M and equity plan share expansion
Authorized common stock increased by 175M shares from 225M to 400M; effective June 13, 2024.
Heron submits PAS to FDA for ZYNRELEF Vial Access Needle to simplify preparation
PAS seeks FDA approval to replace current vented vial spike with new Vial Access Needle (VAN).
Heron Q1 2024 net product sales $34.7M (+17% YoY); net loss per share improves to $(0.02)
Net product sales $34.7M vs $29.6M YoY; net loss per share $(0.02) vs $(0.27).
Heron Therapeutics designates Ira Duarte as principal accounting officer, replacing Lisa Peraza
Ira Duarte appointed principal accounting officer effective March 29, 2024, succeeding Lisa Peraza.
Full-year 2023 oncology care franchise revenue $107.9M exceeded guidance; net product sales up 11% YoY.
FDA approved supplemental NDA for ZYNRELEF to include soft tissue and orthopedic surgical procedures, including foot and ankle.
Heron partners with CrossLink to add ~650 sales reps for ZYNRELEF through 2028
CrossLink adds at least 325 sales reps by July 2024 and 650 by Jan 2025.
Mylan files ANDA for generic APONVIE; Heron to defend 10 patents
Mylan filed paragraph IV certification notice for generic version of APONVIE (aprepitant).
Director Kevin Kotler resigns from Heron Therapeutics board effective Dec 31, 2023
Kevin Kotler resigned from the Board, effective December 31, 2023.
Heron Therapeutics raises FY2023 oncology sales guidance; projects FY2024 EBITDA breakeven
FY2023 net product sales guidance raised to $123-125M; oncology franchise now $104-106M.
Oncology care franchise net product sales $27.3M (Q2 2023) vs $25.1M (Q2 2022); acute care franchise sales $4.5M vs $2.5M.
Heron Therapeutics raises $30M equity, cuts 25% workforce, targets profitability late 2024
Private placement of 20.7M shares at $1.37 and pre-funded warrants for up to 1.16M shares; gross proceeds ~$30M.
Heron Therapeutics appoints Ira Duarte as CFO effective June 16, 2023
Ira Duarte named CFO; previously CFO of Veloxis Pharmaceuticals and held finance roles at BioDelivery Sciences, Chiesi USA, and Ernst & Young.
Kimberly Manhard resigned as EVP, Drug Development effective June 6, 2023, amicably; replaced by William Forbes, Pharm.D., as EVP, Chief Development Officer.
Heron Therapeutics Q1 net product sales up 26% to $29.6M; net loss narrows to $32.8M
Net product sales $29.6M vs $23.5M in Q1 2022, driven by oncology franchise growth of 15%.
John Poyhonen ceases as President and Chief Commercial Officer effective April 30, 2023.
Heron Therapeutics appoints Craig Collard as CEO, Adam Morgan as Chairman
Craig Collard appointed CEO effective April 3, 2023, succeeding Barry Quart who stepped down.
Annual net product sales $107.7M (+25% YoY); Q4 net product sales $30.0M (+45% YoY).
CMS grants pass-through payment status for Heron's APONVIE effective April 1, 2023
CMS approves three-year transitional pass-through status for APONVIE under C-code C9145 starting April 1, 2023.
Heron launches APONVIE IV for PONV prevention; cites 50% fewer vomiting vs ondansetron
APONVIE (aprepitant injectable emulsion) is first IV NK1 receptor antagonist for postoperative nausea and vomiting (PONV).
Appointed Craig Collard, Adam Morgan (Velan), and Kevin Kotler to Board; Board expands to eight directors.
On April 28, 2025, Heron Therapeutics, Inc. (the “ Company ”) announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025
On November 4, 2024, the Board of Directors (the "Board") of Heron Therapeutics, Inc. (the "Company") appointed Michael Kaseta to the Board to serve for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.’s principal accounting officer, replacing Lisa Peraza, the Company’s current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the “Effective Date”).
Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.
On December 20, 2023, Kevin Kotler resigned as a member of the board of directors (the “Board”) of Heron Therapeutics, Inc. (the “Company”), effective December 31, 2023.
On July 20, 2023, by mutual agreement, David Szekeres resigned as Executive Vice President, Chief Operating Officer of the Company, effective July 20, 2023.
appointed Ira Duarte as Chief Financial Officer, effective June 16, 2023
Additionally, effective as of June 6, 2023, William Forbes joined the Company as Executive Vice President, Chief Development Officer.
Kimberly Manhard resigned as Executive Vice President, Drug Development of the Company, effective June 6, 2023.
Also effective April 30, 2023, Michael Mathews will cease to serve as the Senior Vice President Commercial, Acute Care of the Company.
Additionally, effective April 24, 2023, Jason Grillot will join the Company as Vice President, Sales and Marketing, Acute Care.
Effective as of April 30, 2023, John Poyhonen will cease to serve as the President and Chief Commercial Officer of Heron Therapeutics, Inc. (the “Company”).
Max materiality 0.90 · Median 0.65 · Most common event earnings